dabigatran and Gabexate share 5 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.238 means 24% of the combined target set is bound by both compounds. The IDF-weighted score of 0.237 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do dabigatran and Gabexate have in common?
dabigatran and Gabexate share 5 molecular targets with a Jaccard similarity of 24%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can dabigatran and Gabexate be combined?
dabigatran and Gabexate share 5 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: dabigatran or Gabexate?
In the BiohacksAI corpus: dabigatran has 0 PubMed-indexed studies, Gabexate has 300 studies.